Gross Thomas G, Biondi Andrea
Center for Global Health, National Cancer Institute, Rockville, MD, USA.
Paediatric Clinic, University of Milan-Bicocca, San Gerardo Hospital/Fondazione MBBM, Monza, Italy.
Br J Haematol. 2016 May;173(4):651-4. doi: 10.1111/bjh.14030. Epub 2016 Apr 20.
Great advances have been made in the treatment of paediatric non-Hodgkin lymphoma (NHL). In high-income countries (HIC), cure rates now exceed 85%. However, in low- and middle-income countries (LMIC), cure rates remain less than 50%. It is estimated that over 90% of paediatric NHL worldwide occur in LMIC; therefore, even modest improvements in outcome would have significant impact in reducing the burden of paediatric NHL globally. This article will discuss some of the issues required to improve the outcome of paediatric NHL in LMIC using data presented at the Fifth International Symposium on Childhood, Adolescent and Young Adult Non-Hodgkin Lymphoma held in Varese, Italy, 2015 to illustrate these issues. Additionally, potential bi-directional benefits for patients in both LMIC and HIC from future collaborations will be discussed.
小儿非霍奇金淋巴瘤(NHL)的治疗已取得了巨大进展。在高收入国家(HIC),目前治愈率超过85%。然而,在低收入和中等收入国家(LMIC),治愈率仍低于50%。据估计,全球超过90%的小儿NHL病例发生在低收入和中等收入国家;因此,即使是结果上的适度改善也将对减轻全球小儿NHL的负担产生重大影响。本文将利用2015年在意大利瓦雷泽举行的第五届儿童、青少年和青年非霍奇金淋巴瘤国际研讨会上公布的数据,讨论在低收入和中等收入国家改善小儿NHL治疗结果所需的一些问题。此外,还将讨论未来合作可能给低收入和中等收入国家以及高收入国家的患者带来的双向益处。